182 related articles for article (PubMed ID: 9310831)
1. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
[TBL] [Abstract][Full Text] [Related]
2. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
[TBL] [Abstract][Full Text] [Related]
5. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.
Bures R; Morris L; Williamson C; Ramjee G; Deers M; Fiscus SA; Abdool-Karim S; Montefiori DC
J Virol; 2002 Mar; 76(5):2233-44. PubMed ID: 11836401
[TBL] [Abstract][Full Text] [Related]
6. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
7. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
[TBL] [Abstract][Full Text] [Related]
8. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
Pinter A; Honnen WJ; Racho ME; Tilley SA
AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
[TBL] [Abstract][Full Text] [Related]
9. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
10. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.
Gorny MK; Mascola JR; Israel ZR; VanCott TC; Williams C; Balfe P; Hioe C; Brodine S; Burda S; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):213-21. PubMed ID: 9491911
[TBL] [Abstract][Full Text] [Related]
11. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies.
D'Souza MP; Milman G; Bradac JA; McPhee D; Hanson CV; Hendry RM
AIDS; 1995 Aug; 9(8):867-74. PubMed ID: 7576320
[TBL] [Abstract][Full Text] [Related]
13. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
[TBL] [Abstract][Full Text] [Related]
14. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
15. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
[TBL] [Abstract][Full Text] [Related]
16. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
[TBL] [Abstract][Full Text] [Related]
17. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
18. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates.
Candotti D; Rosenheim M; Huraux JM; Agut H
J Virol Methods; 1997 Feb; 64(1):81-93. PubMed ID: 9029533
[TBL] [Abstract][Full Text] [Related]
19. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
[TBL] [Abstract][Full Text] [Related]
20. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
